DE60106002D1 - Behandlung von hematopoietischen zellen mit cxcr4 agonisten - Google Patents

Behandlung von hematopoietischen zellen mit cxcr4 agonisten

Info

Publication number
DE60106002D1
DE60106002D1 DE60106002T DE60106002T DE60106002D1 DE 60106002 D1 DE60106002 D1 DE 60106002D1 DE 60106002 T DE60106002 T DE 60106002T DE 60106002 T DE60106002 T DE 60106002T DE 60106002 D1 DE60106002 D1 DE 60106002D1
Authority
DE
Germany
Prior art keywords
cells
treatment
cxcr4
hematopoietic
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60106002T
Other languages
English (en)
Other versions
DE60106002T2 (de
Inventor
Hassan Salari
Ahmed Merzouk
Lakhdar Arab
R Tudan
Geeta Saxena
J Eaves
Johanne Cashman
Ian Clark-Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Chemokine Therapeutics Corp Canada
Original Assignee
University of British Columbia
Chemokine Therapeutics Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002305036A external-priority patent/CA2305036A1/en
Application filed by University of British Columbia, Chemokine Therapeutics Corp Canada filed Critical University of British Columbia
Publication of DE60106002D1 publication Critical patent/DE60106002D1/de
Application granted granted Critical
Publication of DE60106002T2 publication Critical patent/DE60106002T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/522Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/195Chemokines, e.g. RANTES
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60106002T 2000-04-12 2001-04-12 Behandlung von hämatopoetischen Zellen mit CXCR4 Agonisten Expired - Lifetime DE60106002T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CA002305036A CA2305036A1 (en) 2000-04-12 2000-04-12 Cxcr4 agonist treatment of hematopoietc cells
CA2305036 2000-04-12
US23242500P 2000-09-14 2000-09-14
US232425P 2000-09-14
CA002335109A CA2335109A1 (en) 2000-04-12 2001-02-23 Cxcr4 agonist treatment of hematopoietic cells
CA2335109 2001-02-23
PCT/CA2001/000540 WO2001076615A2 (en) 2000-04-12 2001-04-12 Cxcr4 agonist treatment of hematopoietic cells

Publications (2)

Publication Number Publication Date
DE60106002D1 true DE60106002D1 (de) 2004-11-04
DE60106002T2 DE60106002T2 (de) 2006-02-02

Family

ID=27171219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60106002T Expired - Lifetime DE60106002T2 (de) 2000-04-12 2001-04-12 Behandlung von hämatopoetischen Zellen mit CXCR4 Agonisten

Country Status (9)

Country Link
US (1) US20020165123A1 (de)
EP (1) EP1276493B1 (de)
JP (2) JP2003530355A (de)
AT (1) ATE277628T1 (de)
AU (2) AU5208101A (de)
BR (1) BR0110049A (de)
CA (1) CA2335109A1 (de)
DE (1) DE60106002T2 (de)
WO (1) WO2001076615A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
ATE258444T1 (de) 1998-03-13 2004-02-15 Univ British Columbia Therapeutische chemokine rezeptor antagonisten
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7091310B2 (en) * 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
WO2004094455A2 (en) * 2003-04-16 2004-11-04 Genebact Biotechnologies, Inc. Prophylactic and therapeutic benefits of new class of immune stimulating peptides
FI20040953A0 (fi) * 2004-07-08 2004-07-08 Jari Koistinaho Luuydinsolun stimulointimenetelmä ja luuydinsolu
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
EP1869066B9 (de) * 2005-04-08 2010-02-24 Lonza Ag Peptidsynthese von alpha-helices auf peg-harz
JP4839032B2 (ja) * 2005-07-13 2011-12-14 国立大学法人 岡山大学 ケモカイン受容体作用増強剤
CA2624138A1 (en) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
WO2007079460A2 (en) * 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Design of cxc chemokine analogs for the treatment of human diseases
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20130039882A1 (en) * 2009-10-28 2013-02-14 Henry Ford Health System Method to mitigate injury from radiation exposure
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
KR20210094672A (ko) 2011-05-16 2021-07-29 젠자임 코포레이션 Cxcr4 길항제의 용도
CA2838155C (en) 2011-06-07 2021-10-19 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2760992A (en) * 1956-08-28 Naphthalene
US2530369A (en) * 1948-01-29 1950-11-21 Phillips Petroleum Co Oxidation of aromatic compounds
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP2703893B2 (ja) * 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JP2589094B2 (ja) * 1986-09-13 1997-03-12 中外製薬株式会社 抗悪性腫瘍剤
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE124421T1 (de) * 1989-09-25 1995-07-15 Genetics Inst Verfahren zur wachstumshemmung von stammzellen.
JP3022915B2 (ja) * 1990-07-17 2000-03-21 市郎 東 癌転移抑制剤
NZ246354A (en) * 1991-12-23 1995-10-26 British Bio Technology Stem cell inhibiting proteins and their production and use
PT691988E (pt) * 1993-03-31 2003-02-28 Wellstat Therapeutics Corp Inibidor da proliferacao de celulas estaminais e suas utilizacoes
JP3367581B2 (ja) * 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞
ATE347594T1 (de) * 1994-01-13 2006-12-15 Univ California Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
DE69526395D1 (de) * 1994-08-13 2002-05-23 Roche Diagnostics Gmbh Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5990163A (en) * 1995-01-13 1999-11-23 The Salk Institute For Biological Studies Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
FR2751658B1 (fr) * 1996-07-26 1998-10-02 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) * 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
ATE258444T1 (de) * 1998-03-13 2004-02-15 Univ British Columbia Therapeutische chemokine rezeptor antagonisten

Also Published As

Publication number Publication date
EP1276493B1 (de) 2004-09-29
AU2001252081B9 (en) 2005-05-05
JP2009143942A (ja) 2009-07-02
US20020165123A1 (en) 2002-11-07
JP2003530355A (ja) 2003-10-14
AU5208101A (en) 2001-10-23
DE60106002T2 (de) 2006-02-02
WO2001076615A2 (en) 2001-10-18
AU2001252081B2 (en) 2004-12-23
WO2001076615A3 (en) 2002-02-28
EP1276493A2 (de) 2003-01-22
CA2335109A1 (en) 2001-10-12
BR0110049A (pt) 2003-07-01
ATE277628T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
DE60106002D1 (de) Behandlung von hematopoietischen zellen mit cxcr4 agonisten
Maan et al. Cell recruitment by amnion chorion grafts promotes neovascularization
Mori et al. Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia
King et al. Role of White Blood Cells in Blood‐and Bone Marrow‐Based Autologous Therapies
Gallagher et al. Hyperbaric oxygen and bone marrow–derived endothelial progenitor cells in diabetic wound healing
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
CA2567177A1 (en) Genetically engineered cells for therapeutic applications
Harper et al. Dermatological aspects of the use of Cyclosporin A for prophylaxis of graft‐versus‐host disease
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
EP2089047A2 (de) Zusammensetzungen und verfahren zum schutz und zur regeneration von herzgewebe
ATE440602T1 (de) Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
Tsutsui et al. Treatment of cardiac disease by inhalation of atmospheric pressure plasma
DE69634982D1 (de) Verfahren zur steigerung von hematopoietischen zellen
Sun et al. B cell lymphoma-2-modified bone marrow-derived mesenchymal stem cells transplantation for the treatment of diabetes mellitus-induced erectile dysfunction in a rat model
EP1171165A4 (de) Injektion von autologem knochenmark in den herzmuskel
EA200500757A1 (ru) Новое применение декстрансульфата
Gehrig et al. Emerging drugs for treating skeletal muscle injury and promoting muscle repair
WO2000061755A3 (en) Secreted human proteins
Kwon et al. Regeneration of Chronic Rotator Cuff Tear in a Rabbit Model: Synergetic Benefits of Human Umbilical Cord Blood‐Derived Mesenchymal Stem Cells, Polydeoxyribonucleotides, and Microcurrent Therapy
LoBue Humoral Control of Growth And Differentiation: Vertebrate Regulatory Factors
Wu et al. Extracellular Vesicles Isolated From Hypoxia-Preconditioned Adipose-Derived Stem Cells Promote Hypoxia-Inducible Factor 1α–Mediated Neovascularization of Random Skin Flap in Rats
Fromes et al. The tetrapeptide acetyl‐serine‐aspartyl‐lysine‐proline improves skin flap survival and accelerates wound healing
ATE540968T1 (de) Alpha-fetoproteinpeptide und deren verwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition